In theory, yes, once survodutide becomes commercially available
Industry 2 min read Drug withdrawal rebound remains an unmet need in GLP-1R agonist space: GlobalData The rebound effect upon GLP-1R agonists withdrawal needs to be investigated further and new drug developments should aim to mitigate this big limitation and find ways in which GLP-1R agonists could be used as short-term therapies without causing weight regain and cardiometabolic risk reversal
This ramp-up schedule allows your body to get used to semaglutide, reducing potential side effects
E.HoltM
Timing depends on diabetes status, baseline results, other medications, dose changes, kidney risk, gastrointestinal symptoms, and treatment goals
Julie Schwartz, RD: It's not a magic bullet